Cann Group Ltd, a leading Australian medicinal cannabis company, embodies a strong set of values and corporate philosophy. The company is committed to producing high-quality medical cannabis products to improve the lives of patients. Cann Group values innovation and sustainability, constantly seeking new ways to enhance their cultivation and manufacturing processes. With a focus on research and development, they aim to continually expand their product offerings and provide effective and safe treatments. Cann Group Ltd prides itself on its dedication to investors, transparency, and regulatory compliance, ensuring a trustworthy and reliable approach to business.

Cann Group Ltd is primarily present in Australia.

Cann Group Ltd has achieved several significant milestones in its operations. Firstly, the company became the first Australian business to obtain a license to cultivate medicinal cannabis for research purposes in 2017. This achievement positioned Cann Group Ltd as a pioneer in the country's emerging medicinal cannabis industry. Additionally, the company successfully completed its first commercial cannabis harvest in 2018, marking another important milestone. Furthermore, Cann Group Ltd obtained its crucial Manufacture License in 2019, allowing the company to produce and distribute medicinal cannabis products in Australia. These milestones highlight Cann Group Ltd's commitment to advancing the availability and quality of medicinal cannabis within the country's market.

Cann Group Ltd is an Australian company that specializes in cultivating and producing medical cannabis. Established in 2014, Cann Group was the first to be granted a license to cultivate and research cannabis for medicinal purposes in Australia. With a strong commitment to quality and compliance, the company has built state-of-the-art facilities and established strategic partnerships to expand its operations. Cann Group is dedicated to providing safe and effective cannabis-based products to improve patient outcomes and is at the forefront of the rapidly growing medicinal cannabis industry in Australia.

The main competitors of Cann Group Ltd in the market include other companies involved in the production and distribution of medical cannabis and cannabis-related products. Some significant competitors of Cann Group Ltd may include AusCann Group Holdings Ltd, Althea Group Holdings Ltd, and Little Green Pharma Ltd. These companies operate in the same industry and focus on the cultivation, manufacturing, and sale of medical cannabis products. Cann Group Ltd competes with these companies to gain market share, secure partnerships, and expand their customer base in the rapidly growing cannabis industry.

Cann Group Ltd is primarily active in the cannabis industry.

Cann Group Ltd is an Australian company that operates in the medicinal cannabis industry. Its business model revolves around cultivation, manufacturing, and distribution of pharmaceutical-grade cannabis products and providing services to the medicinal cannabis sector. With a focus on research and development, Cann Group aims to support healthcare professionals and patients by developing high-quality therapeutic products derived from cannabis plants. The company's expertise lies in the production of standardized cannabis cultivars, extraction, and development of new formulations to meet the evolving needs of the medical industry. Cann Group Ltd strives to establish itself as a leading player in the medicinal cannabis market.

P/E-lukua ei voida tällä hetkellä laskea kohteelle Cann Group.

KUV:tä ei voida tällä hetkellä laskea Cann Group osalta.

AlleAktien Laatuscore Cann Group on 4/10.

Liikevaihtoa ei voida tällä hetkellä laskea yritykselle Cann Group.

Voitto ei voida tällä hetkellä laskea yritykselle Cann Group.

Cann Group Ltd is an Australian company specializing in the medical cannabis market. Its business model involves producing, developing, and distributing cannabis for medical use. The company serves various segments, such as the market for human medical products, the veterinary sector, and the recreational and wellness sector. The company is well positioned to benefit from the growing demand for medical cannabis, CBD products for pets, and recreational products.

Cann Group maksaa osinkoa 0 AUD, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea Cann Group:lle tai yhtiö ei maksa osinkoa.

Cann Group:n ISIN on AU000000CAN2.

Cann Group:n WKN on A2DSUQ.

Cann Group:n tunnus on CAN.AX.

Viimeisen 12 kuukauden aikana Cann Group maksoi osinkoa edestä. Tämä vastaa noin osinkotuottoa. Seuraavan 12 kuukauden aikana Cann Group maksanee ennusteiden mukaan 0 AUD osingon.

Cann Group:n tämänhetkinen osinkotuotto on .

Cann Group maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina .

Cann Group maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 0 AUD suuruisia osinkoja. Tämä vastaa 0 % osinkotuottoa.

Cann Group kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän Cann Group osingon 8.7.2024, jonka suuruus on 0 AUD, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 8.7.2024.

Viimeisin osinko maksettiin 8.7.2024.

Vuonna 2023 Cann Group maksoi 0 AUD osinkoina.

Cann Group:n osingot maksetaan AUDssa.